

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Account L.L.P. No.: 50-1212/MONS:016US.

AMENDMENT

Please amend the specification by replacing the sequence listing with the copy of the sequence listing found on the enclosed compact disk.

REMARKS

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated January 21, 2003 (copy enclosed), Applicants have amended the specification to include the required Sequence Listing. A substitute computer readable form (CRF) copy of the enclosed substitute Sequence Listing and a Statement As Required Under 37 C.F.R. § 1.825(a) and (b) And Statement As Required Under 37 C.F.R. § 1.821(g) are also submitted herewith. No new matter is introduced by this amendment.

Should the Examiner have any questions or comments regarding this matter, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,



Robert E. Hanson
Reg. No. 42,628
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3085

Date: February 13, 2003